SORRENTO THERAPEUTICS INC (SRNE) Stock Analyst Earnings Estimates
NASDAQ:SRNE - Nasdaq - US83587F2020 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.4M 48.11% | 40M 27.39% | 52.904M 32.26% | 58.222M 10.05% | 53.272M -8.50% | 207.44M 289.40% | |
| EBITDA YoY % growth | -248.41M -75.74% | -233.59M 5.97% | -388.989M -66.53% | N/A | N/A | N/A | |
| EBIT YoY % growth | -259.4M -72.47% | -244.6M 5.71% | -401.451M -64.13% | -404.9M -0.86% | -394.552M 2.56% | -238.206M 39.63% | |
| Operating Margin | -826.11% | -611.50% | -758.83% | -695.44% | -740.64% | -114.83% | |
| EPS YoY % growth | -2.25 -52.03% | -1.19 47.11% | -1.43 -20.17% | -1.20 15.83% | -0.90 25.00% | -0.53 41.81% |
All data in USD
| Q4 / 22 | |
|---|---|
| EPS Q2Q % growth | -0.23 50.09% |
| Revenue Q2Q % growth | 16.905M 29.28% |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -97.046M 15.32% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | -0.20 50.00% | -0.26 | 0.06 | 23.11% |
| Q2 2022 Q2Q % growth | -0.54 5.26% | -0.26 | -0.29 | -111.76% |
| Q1 2022 Q2Q % growth | -1,732.00% | -0.16 | % | |
| Q4 2021 Q2Q % growth | -0.47 -74.07% | -0.30 | -0.17 | -56.20% |
| Q3 2021 Q2Q % growth | -0.40 -21.21% | -0.23 | -0.17 | -70.50% |
| Q2 2021 Q2Q % growth | -0.57 -58.33% | -0.20 | -0.37 | -179.41% |
| Q1 2021 Q2Q % growth | 0.01 104.35% | 0.38 | -0.37 | -97.40% |
| Q4 2020 Q2Q % growth | -0.27 34.15% | 2.77 | -3.04 | -109.75% |
| Q3 2020 Q2Q % growth | -0.33 34.00% | -0.21 | -0.12 | -57.82% |
| Q2 2020 Q2Q % growth | -0.36 21.74% | -0.22 | -0.14 | -60.43% |
| Q1 2020 Q2Q % growth | -0.23 73.86% | -0.20 | -0.03 | -12.75% |
| Q4 2019 Q2Q % growth | -0.41 | -0.39 | -0.02 | -4.41% |
| Q3 2019 Q2Q % growth | -0.50 | -0.44 | -0.06 | -14.00% |
| Q2 2019 Q2Q % growth | -0.46 | -0.41 | -0.05 | -12.75% |
| Q1 2019 Q2Q % growth | -0.88 | -0.34 | -0.54 | -156.26% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | 17.4M 44.25% | 13.867M | 3.533M | 25.48% |
| Q2 2022 Q2Q % growth | 11.461M -58.72% | 19.128M | -7.667M | -40.08% |
| Q1 2022 Q2Q % growth | 18.385M 28.57% | 25.52M | -7.135M | -27.96% |
| Q4 2021 Q2Q % growth | 13.076M 13.70% | 15.429M | -2.353M | -15.25% |
| Q3 2021 Q2Q % growth | 12.062M 2.22% | 10.383M | 1.679M | 16.17% |
| Q2 2021 Q2Q % growth | 27.766M 208.51% | 10.329M | 17.437M | 168.82% |
| Q1 2021 Q2Q % growth | 14.3M 85.71% | 17.598M | -3.298M | -18.74% |
| Q4 2020 Q2Q % growth | 11.5M -11.54% | 1.032B | -1.021B | -98.89% |
| Q3 2020 Q2Q % growth | 11.8M 103.45% | 10.519M | 1.281M | 12.18% |
| Q2 2020 Q2Q % growth | 9M 38.46% | 8.16M | 840K | 10.29% |
| Q1 2020 Q2Q % growth | 7.7M 26.23% | 10.2M | -2.5M | -24.51% |
| Q4 2019 Q2Q % growth | 13M | 6.936M | 6.064M | 87.43% |
| Q3 2019 Q2Q % growth | 5.8M | 7.237M | -1.437M | -19.86% |
| Q2 2019 Q2Q % growth | 6.5M | 7.905M | -1.405M | -17.77% |
| Q1 2019 Q2Q % growth | 6.1M | 8.182M | -2.082M | -25.45% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 6.12% | 0% | 0% |
| Revenue | 0% | 21.31% | 0% | 6.77% |